Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
OTCMKTS:ZLDPF

Zealand Pharma A/S 8/14/2025 Earnings Report

Zealand Pharma A/S logo
$45.30 0.00 (0.00%)
As of 05/4/2026 02:40 PM Eastern
ProfileEarnings HistoryForecast

Zealand Pharma A/S EPS Results

Actual EPS
$16.06
Consensus EPS
$16.72
Beat/Miss
Missed by -$0.66
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.43 billion
Expected Revenue
$9.18 billion
Beat/Miss
Missed by -$7.75 billion
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Thursday, May 7, 2026, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of "Moderate Buy" from Brokerages
May 2 at 5:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30754371
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
May 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-convenes-extraordinary-general-meeting-on-may-26-2026-1036094394
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
May 5 at 1:00 AM  |  Profits Run (Ad)
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
April 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-conference-call-on-may-7-at-2pm-cet-8am-et-to-present-first-quarter-2026-financial-results-1036087497
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic ...
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-announces-boehringer-ingelheim-s-novel-glucagon-glp-1-dual-agonist-survodutide-achieved-significant-weight-loss-of-16-6-delivering-meaningful-metabolic-improvement-in-people-with-1036070434
Zealand says GLP-1 developed with Boehringer led to 17% weight loss in late-stage trial
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/zealand-says-glp-1-developed-with-boehringer-led-to-17-weight-loss-in-late-stage-trial/ar-AA21W1yv
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access.

Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.

View Zealand Pharma A/S Profile
Earnings Tools